Neoadjuvant immunotherapy for resectable hepatocellular carcinoma
- PMID: 35550049
- DOI: 10.1016/S2468-1253(22)00083-8
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma
Conflict of interest statement
I declare no competing interests.
Comment in
-
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma - Authors' reply.Lancet Gastroenterol Hepatol. 2022 Jun;7(6):505. doi: 10.1016/S2468-1253(22)00122-4. Lancet Gastroenterol Hepatol. 2022. PMID: 35550051 No abstract available.
Comment on
-
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229. doi: 10.1016/S2468-1253(21)00385-X. Epub 2022 Jan 20. Lancet Gastroenterol Hepatol. 2022. PMID: 35065058 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
